Exposure-adjusted safety analyses of the VISION phase 3 trial of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
ASCO GU 2022: Longer term safety analyses for 177 Lu-PSMA
Related Articles
Health Perceptions, Multimorbidity, and New Fractures and Mortality After a Fracture
This cohort study investigates associations of multimorbidity and self-related health measures with risk of subsequent fractures and mortality among patients aged 45 years or older…
Nurse Practitioners Share their Experiences With National Workforce Survey
Learn more about this important survey and how to participate. Media Contact: Bryan Black AUSTIN, TEXAS β The latest national workforce survey has just been…
MedNews Week
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Senior monitoring systems: How to find the option that’s best for your loved one
Read on to learn more about what senior monitoring systems are, when to consider one and key features to look for if you do.
Myeloma Paper of the Day, April 25th, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, April 25th, suggested by Robert Orlowski / cancer, MajesTEC-1 trial, MD Anderson Cancer Center, multiple myeloma, Myeloma, Myeloma
Understanding the Value of the Home as a Healthcare Site
A new FDA program aims to develop strategies and guidelines for health systems delivering care in the patientβs home
Babies of dengue-infected pregnant women shown to be at high risk for poor health in first years of life
The newborns had a 67% and 133% greater risk of being classified as very and extremely low birth weight, respectively.Β
Know Diabetes by Heartβ’ | Managing Type 2 Diabetes and Heart Risks
Know Diabetes by Heartβ’ provides resources for individuals and professionals and empowers those living with type 2 diabetes to take charge of their health.
Study links mode of birth, antibiotic use to more antibiotic resistance genes in infants
Researchers say the findings could aid development of interventions targeting the microbiome of mothers and their infants.
Impaired sense of smell still common 1 year after COVID-19
Participants with a history of COVID-19 were more likely to experience some degree of smell loss compared with those without a history.